Summary of Significant Accounting Policies - Additional Information (Detail)	3 Months Ended	9 Months Ended
	Dec. 31, 2019 USD ($)	Sep. 30, 2019 USD ($) Segment	Sep. 30, 2018 USD ($)	Jan. 01, 2019 USD ($)	Dec. 31, 2018 USD ($)
Summary Of Significant Accounting Policies [Line Items]
Accumulated deficit		$ (176,173,000)			$ (129,719,000)
Cash flow from operations		(35,177,000)	$ (28,782,000)
Cash and cash equivalents		17,785,000			24,301,000
Short-term investments		$ 88,496,000			86,529,000
Cash and cash equivalents with original maturities		three months or less
Carrying value of IPR&D		$ 600,000
Changes in carrying value of goodwill		0
Impairment of goodwill		7,420,000
Impairment of IPR&D			$ 21,692,000
Operating lease, liability		872,000
Present value of remaining lease payments		929,000
Operating lease, right-of -use asset		$ 800,000
Discounted using incremental borrowing rate		8.50%
Number of operating segments | Segment		1
Date of agreement		Oct. 08, 2018
Contingent milestones or co-marketing commitments met or incurred		$ 0
Contingent milestones or co-marketing commitments met or remunerated		0
Contingent Milestones Or Co Marketing Commitments Accrued		$ 0
Active Pharmaceutical Ingredients [Member]
Summary Of Significant Accounting Policies [Line Items]
Agreement description		Under a manufacture and supply agreement with the active pharmaceutical ingredients (“API”) manufacturer, Savara must make certain payments to the API manufacturer upon achievement of the milestones outlined in the table set forth below. Additionally, upon first receipt of marketing approval by Savara from a regulatory authority in a country for a product containing the API for therapeutic use in humans and ending the earlier of (i) ten (10) years thereafter or (ii) the date a biosimilar of such product is first sold in such country, Savara shall pay the API manufacturer a royalty equal to low-single digits of the net sales in that country.
aPAP [Member] | Japan [Member]
Summary Of Significant Accounting Policies [Line Items]
Percentage of other contingent milestone payments associated with specific regulatory and filing activities		50.00%
Other contingent milestone payments associated with specific regulatory and filing activities		$ 750,000
License agreement development and commercialization cost		0
aPAP [Member] | Japan [Member] | Maximum [Member]
Summary Of Significant Accounting Policies [Line Items]
Other contingent milestone payments associated with specific regulatory and filing activities		$ 800,000
NTM [Member]
Summary Of Significant Accounting Policies [Line Items]
Royalty percent on net sale after publication of the intellectual property		0.50%
Royalty percent on net sale prior publication of the intellectual property		0.25%
Nebulizer | Maximum [Member]
Summary Of Significant Accounting Policies [Line Items]
Royalty percent on net sale		5.00%
Nebulizer | Minimum [Member]
Summary Of Significant Accounting Policies [Line Items]
Royalty percent on net sale		3.50%
ASC 842
Summary Of Significant Accounting Policies [Line Items]
Operating lease, liability				$ 1,400,000
Present value of remaining lease payments				1,500,000
Operating lease, right-of -use asset				$ 1,400,000
Discounted using incremental borrowing rate				8.50%
Savara ApS [Member]
Summary Of Significant Accounting Policies [Line Items]
Research and development tax credits		22.00%
Research and development tax credits receivable		$ 1,600,000
Savara ApS [Member] | Prepaid Expenses and Other Current Assets [Member]
Summary Of Significant Accounting Policies [Line Items]
Research and development tax credits receivable					$ 800,000
Savara ApS [Member] | Other Non-Current Assets [Member]
Summary Of Significant Accounting Policies [Line Items]
Research and development tax credits receivable		$ 800,000
Savara Australia Pty Limited [Member]
Summary Of Significant Accounting Policies [Line Items]
Research and development tax credits		43.50%
Savara Australia Pty Limited [Member] | Prepaid Expenses and Other Current Assets [Member]
Summary Of Significant Accounting Policies [Line Items]
Research and development tax credits receivable		$ 300,000
Scenario, Forecast [Member]
Summary Of Significant Accounting Policies [Line Items]
Impairment of goodwill	$ 19,400,000
Reduction of carrying value of goodwill to fair value	0
Scenario, Forecast [Member] | IPR&D [Member]
Summary Of Significant Accounting Policies [Line Items]
Impairment of IPR&D	$ 0